Tacrolimus associated posterior reversible encephalopathy syndrome - A case series and review

Susmitha Apuri, Kristin Carlin, Edward Bass, Phuong Thuy Nguyen, John N. Greene

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Tacrolimus is an immunosuppressive drug mainly used to lower the risk of transplant rejection in individuals who are post solid organ or hematopoietic transplantation. It is a macrolide which reduces peptidyl-propyl isomerase activity and inhibits calcineurin, thus inhibiting T-lymphocyte signal transduction and interleukin-2 (IL-2) transcription. It has been associated with Posterior Reversible Encephalopathy Syndrome (PRES), a disease of sudden onset that can present as a host of different symptoms, depending on the affected area of the brain. While infectious causes of encephalopathy must always be entertained, the differential diagnosis should also include PRES in the appropriate context. We report three cases of PRES in patients with acute myeloid leukemia (AML) placed on tacrolimus after receiving a bone marrow transplant (BMT). The focus of this review is to enhance clinical recognition of PRES as it is related to an adverse effect of Tacrolimus in the setting of hematopoietic transplantation.

Original languageEnglish (US)
Article numbere2014014
JournalMediterranean Journal of Hematology and Infectious Diseases
Issue number1
StatePublished - 2014

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases


Dive into the research topics of 'Tacrolimus associated posterior reversible encephalopathy syndrome - A case series and review'. Together they form a unique fingerprint.

Cite this